It has been well established that the increased tumour-infiltrating CD4+ and CD8+ T cells in patients with MSI-H CRC (due to the increased mutator phenotype of the tumour stimulating the host immune response) significantly improved patient outcomes when treated with immunotherapy when compared to MSS CRC with decreased immune response [53, 54]. This evidence concerns the gene CD8A and colorectal carcinoma.